GANDOLFO, CLAUDIA
 Distribuzione geografica
Continente #
EU - Europa 2.888
NA - Nord America 2.594
AS - Asia 1.261
SA - Sud America 260
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 7.050
Nazione #
US - Stati Uniti d'America 2.553
RU - Federazione Russa 734
IT - Italia 533
IE - Irlanda 494
SG - Singapore 489
GB - Regno Unito 383
CN - Cina 327
BR - Brasile 214
SE - Svezia 181
DE - Germania 148
HK - Hong Kong 112
VN - Vietnam 109
FI - Finlandia 106
FR - Francia 98
UA - Ucraina 62
KR - Corea 52
IN - India 51
PL - Polonia 29
ES - Italia 26
NL - Olanda 21
BE - Belgio 19
TR - Turchia 18
CA - Canada 17
MX - Messico 16
BD - Bangladesh 15
ZA - Sudafrica 12
AR - Argentina 11
AT - Austria 11
PK - Pakistan 11
CI - Costa d'Avorio 10
IQ - Iraq 10
JP - Giappone 10
CO - Colombia 9
IM - Isola di Man 9
CZ - Repubblica Ceca 8
ID - Indonesia 7
AE - Emirati Arabi Uniti 6
PE - Perù 6
EC - Ecuador 5
IL - Israele 5
MA - Marocco 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
BG - Bulgaria 4
CL - Cile 4
IR - Iran 4
LT - Lituania 4
MT - Malta 4
PY - Paraguay 4
DZ - Algeria 3
EU - Europa 3
JO - Giordania 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
VE - Venezuela 3
AL - Albania 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EG - Egitto 2
KE - Kenya 2
KZ - Kazakistan 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
MU - Mauritius 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PW - Palau 1
QA - Qatar 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 7.050
Città #
Dublin 479
Dallas 322
Singapore 308
Southend 308
Ashburn 231
Chandler 218
Fairfield 204
Moscow 204
Santa Clara 177
Siena 164
Hong Kong 111
Beijing 104
Wilmington 91
Ann Arbor 75
Houston 75
Woodbridge 74
New York 72
Cambridge 71
Seattle 69
Princeton 68
Helsinki 63
Munich 58
Milan 56
Los Angeles 53
Jacksonville 52
Seoul 50
Rome 40
Hefei 39
Florence 33
The Dalles 30
Warsaw 28
Fremont 27
Ho Chi Minh City 26
Dong Ket 25
Menlo Park 24
Hanoi 20
São Paulo 18
San Mateo 17
Shanghai 17
Turku 17
Brussels 16
Buffalo 15
Boardman 14
Málaga 14
Lauterbourg 13
Nanjing 13
Redondo Beach 13
San Diego 13
Lappeenranta 12
Nuremberg 12
Lancaster 11
Abidjan 10
Düsseldorf 10
London 10
Montreal 10
Portsmouth 10
Atlanta 9
Chennai 9
Chicago 9
Columbus 9
Dearborn 9
Denver 9
Falls Church 9
Frankfurt am Main 9
Tokyo 9
Boston 8
Council Bluffs 8
Douglas 8
Izmir 8
Bengaluru 7
Karlsruhe 7
Messina 7
Phoenix 7
Poplar 7
Rio de Janeiro 7
Shenyang 7
Espoo 6
Norwalk 6
Orem 6
Stockholm 6
Vienna 6
Ankara 5
Brooklyn 5
Falkenstein 5
Haiphong 5
Mexico City 5
Poli 5
Tashkent 5
Washington 5
Belo Horizonte 4
Bogotá 4
Cagliari 4
Campofilone 4
Dubai 4
Guangzhou 4
Guarulhos 4
Hebei 4
Istanbul 4
Johannesburg 4
Manchester 4
Totale 4.590
Nome #
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease 355
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 314
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 299
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 254
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 250
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome 246
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 242
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 235
Host-pathogen interaction: study of Toscana virus 229
Whole-Genome Sequence of SARS-CoV-2 Isolate Siena-1/2020 221
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 203
Identification of a neutralizing epitope on tosv gn glycoprotein 191
Immune-inflammatory markers predict the outcome of metastatic colorectal cancer patients treated with the thymidylate synthase poly-epitope peptide (TSPP) vaccine: results from a multi-arm TSPP/VAC phase lb program 190
Seroprevalence to measles virus after vaccination or natural infection in an adult population, in Italy 188
Infection prevention in endoscopy practice; comparative evaluation of reusable vs single use endoscopic valves 172
Omicron infection evokes cross-protection against SARS-CoV-2 variants in vaccinees 167
Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: Results from a large-scale screening program based on rapid serological testing 166
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection 163
Alcohol intake and the risk of intracerebral hemorrhage in the elderly: The MUCH-Italy 159
Toscana virus non-structural protein NSs acts as E3 ubiquitin ligase promoting RIG-I degradation 157
Human Polymorphonuclear Cells Support Zika Virus to Cross Endothelial Monolayer and Access Bloodstream 156
Neutralizing antibody response of vaccinees to SARS-CoV-2 variants 155
Ubiquitin and not only unfolded domains drives toscana virus non-structural NSs protein degradation 155
Infectious Toscana virus in seminal fluid of young man returning from Elba Island, Italy 155
Efficient inactivation of sars-cov-2 and other rna or dna viruses with blue led light 152
Comparative performance of a new sars-cov-2 rapid detection system 152
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 147
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era 147
How long can SARS-CoV-2 persist in human corpses? 147
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 146
Epidemiology of Toscana virus in South Tuscany over the years 2011-2019 140
Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified? 132
Toscana virus infects dendritic and endothelial cells opening the way for the central nervous system 129
Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience 126
Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine 117
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion 113
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix 106
null 103
Detection of SARS-CoV-2 N protein allelic variants by rapid high-throughput CLEIA antigen assay 90
Validation of Two Commercial Multiplex Real-Time PCR Assays for Detection of SARS-CoV-2 in Stool Donors for Fecal Microbiota Transplantation 82
SARS-CoV-2 n protein targets TRIM25-mediated RIG-I activation to suppress innate immunity 81
Truncation of the C-terminal region of Toscana Virus NSs protein is critical for interferon-β antagonism and protein stability 74
Totale 7.206
Categoria #
all - tutte 25.517
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.517


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021502 0 0 0 0 0 103 77 57 58 83 39 85
2021/2022529 34 33 24 39 23 27 21 16 99 45 57 111
2022/2023758 42 92 98 80 75 154 18 74 59 25 25 16
2023/2024862 24 51 70 47 35 212 307 24 7 14 16 55
2024/20251.440 57 61 158 94 163 98 94 94 160 80 157 224
2025/20262.199 228 383 282 460 733 113 0 0 0 0 0 0
Totale 7.206